- Home
- CEAD vs CDT Comparison
CEAD vs CDT Comparison
Compare CEAD & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEAD
- CDT
- Stock Information
- Founded
- CEAD 2009
- CDT 2019
- Country
- CEAD United States
- CDT United States
- Employees
- CEAD N/A
- CDT N/A
- Industry
- CEAD Industrial Machinery/Components
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- CEAD Industrials
- CDT Health Care
- Exchange
- CEAD Nasdaq
- CDT Nasdaq
- Market Cap
- CEAD 6.4M
- CDT 5.2M
- IPO Year
- CEAD N/A
- CDT N/A
- Fundamental
- Price
- CEAD $7.78
- CDT $0.54
- Analyst Decision
- CEAD
- CDT
- Analyst Count
- CEAD 0
- CDT 0
- Target Price
- CEAD N/A
- CDT N/A
- AVG Volume (30 Days)
- CEAD 6.8K
- CDT 7.4M
- Earning Date
- CEAD 05-13-2025
- CDT 05-13-2025
- Dividend Yield
- CEAD N/A
- CDT N/A
- EPS Growth
- CEAD N/A
- CDT N/A
- EPS
- CEAD N/A
- CDT N/A
- Revenue
- CEAD $2,803,470.00
- CDT N/A
- Revenue This Year
- CEAD N/A
- CDT N/A
- Revenue Next Year
- CEAD N/A
- CDT N/A
- P/E Ratio
- CEAD N/A
- CDT N/A
- Revenue Growth
- CEAD N/A
- CDT N/A
- 52 Week Low
- CEAD $5.60
- CDT $0.51
- 52 Week High
- CEAD $12.26
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- CEAD 42.56
- CDT 36.40
- Support Level
- CEAD $7.75
- CDT $0.52
- Resistance Level
- CEAD $8.77
- CDT $1.01
- Average True Range (ATR)
- CEAD 0.48
- CDT 0.16
- MACD
- CEAD -0.05
- CDT 0.02
- Stochastic Oscillator
- CEAD 6.15
- CDT 3.43
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.